<?xml version="1.0" encoding="UTF-8"?>
<p id="para0010">Most laboratory-confirmed cases of A(H7N9) virus infection have been severely ill and have required ICU admission.
 <xref rid="bib0001" ref-type="bibr">
  <sup>1</sup>
 </xref> Early neuraminidase inhibitor treatment appears to shorten the duration of viral shedding and improve outcome of A(H7N9) virus-infected patients.
 <xref rid="bib0012" ref-type="bibr">
  <sup>12</sup>
 </xref> However, the emergence of neuraminidase inhibitor resistance in A(H7N9) and other avian influenza A viruses highlights the need for additional therapeutic options.
 <xref rid="bib0013" ref-type="bibr">
  <sup>13</sup>
 </xref> Convalescent plasma may be a potential treatment for severe influenza,
 <xref rid="bib0014" ref-type="bibr">
  <sup>14</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0015" ref-type="bibr">
  <sup>15</sup>
 </xref> and was used in the treatment of one A(H7N9) patient who did not respond to oseltamivir treatment.
 <xref rid="bib0016" ref-type="bibr">
  <sup>16</sup>
 </xref> Convalescent plasma or post-vaccination plasma were also used for treatment of A(H5N1) patients.
 <xref rid="bib0017" ref-type="bibr">
  <sup>17</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0018" ref-type="bibr">
  <sup>18</sup>
 </xref> Beigel and colleagues conducted the first randomized controlled trial of immune plasma in severe seasonal influenza and reported evidence of clinical benefit, primarily limited to participants who were treated within 4 days of illness onset.
 <xref rid="bib0015" ref-type="bibr">
  <sup>15</sup>
 </xref> A larger phase III trial is now ongoing [NCT02572817].
</p>
